Crowdfund and discover promising therapeutics via Molecule

21 Feb 2019

Connecting scientists, patients, and industry to advance drug development in a collaborative open market.

Linum Labs, a software development studio that builds blockchain-based solutions, has announced Molecule, a market platform to accelerate innovation in the pharmaceutical and biotech industry.

Crowdfund and discover promising therapeutics via Molecule

Molecule connects scientists, patients, and industry to advance drug development in a collaborative open market. By creating an open market for participants to crowdfund and discover promising therapeutics, it aims to solve core issues in the industry’s current business and innovation model.

“The pharmaceutical industry faces an innovation crisis caused by the challenges around drug development and the monopolisation of IP,” says Paul Kohlhaas, CEO of Linum Labs. “Bringing a drug to market is a high-cost, high-risk, and slow endeavour, and it is generally large organisations that single-handedly shoulder these burdens, leading to unnecessarily high prices and friction around innovation.”

“These large organisations also shelve any IP that is perceived to have less revenue potential or difficult and costly development paths. This has had a significant negative effect on innovation in the pharmaceutical industry, which has moved away from a high-risk pioneering approach. Instead, we have a low-risk high-ticket size environment where R&D is reduced and only ‘blockbuster drugs’ get approved for development, regardless of their potential impact on overall societal health and wellbeing.”

Molecule aims to transform the pharma industry by providing a platform for crowdsourcing funding and research, reducing risk for investors and IP creators while creating more diverse and inclusive treatments for patients and consumers.

Swiss-based Linum Labs began developing Molecule in early 2018 and intends to build out the platform as an open source industry initiative on behalf of the Molecule Foundation, a Swiss non-profit.

The next phase of development will include testing with an early user cohort and further iterations of the initial prototype, leading into a minimum viable product. This will be supported by a financing round due to start in Q2 2019.

Read More

Related news

Follicum files patent application for new topical formulation for hair loss

Follicum files patent application for new topical formulation for hair loss

30 Apr 2019

Using easy-to-apply cream instead of direct scalp injection would extend patent protection by 8 years.

Read more 
Hovione Technology acquires global rights to new pulmonary inhaler device

Hovione Technology acquires global rights to new pulmonary inhaler device

15 Apr 2019

The Papillon DPI is a single-part, blister-based, reusable inhaler, suitable for both chronic and acute treatments.

Read more 
Isotype-specific secondary antibodies for improved signal detection

Isotype-specific secondary antibodies for improved signal detection

10 Apr 2019

Offers an alternative to cross-adsorbed secondary antibodies when absolute specificity is required.

Read more 
Sterling Pharma to acquire CiVentiChem in the US

Sterling Pharma to acquire CiVentiChem in the US

9 Apr 2019

The acquisition will enhance the CDMO's chemistry development capabilities to support pre-clinical and early phase clinical supply.

Read more 
Catalent expands OptiMelt hot melt extrusion capabilities

Catalent expands OptiMelt hot melt extrusion capabilities

4 Apr 2019

The investment includes the addition of equipment to enhance development capabilities for preclinical and early clinical phase development, as well as adding downstream processing technologies to support HME formulations.

Read more 
'Drugs from bugs' joint venture

'Drugs from bugs' joint venture

4 Apr 2019

Lonza and Chr. Hansen create a strategic joint venture to become the partner of choice for developing and manufacturing live biotherapeutic products for pharma and biotech customers.

Read more 
Curcumin and pomegrantes - new hope for Alzheimer’s prevention?

Curcumin and pomegrantes - new hope for Alzheimer’s prevention?

3 Apr 2019

New research at University of Warwick will test how curcumin kick-starts the brain’s cleansing of damaging plaques and cells.

Read more 
MedPharm's appointment with Destiny

MedPharm's appointment with Destiny

28 Mar 2019

Global contract provider to develop new XF-platform drug formulations for the treatment of a number of topically treated infections, including diabetic foot ulcers and ophthalmic infections.

Read more 
Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy

Third Sartorius Research Xchange Forum 2019 focuses on CAR-T cell therapy

13 Mar 2019

Event for experts from academia and industry, including talks, live demo sessions, and panel discussion.

Read more 
Envigo launches PATHWAY to enable FIH clinical trials

Envigo launches PATHWAY to enable FIH clinical trials

11 Mar 2019

PATHWAY manages the complexity of the entire safety assessment process on behalf of the company’s pharmaceutical and biotechnology customers.

Read more